Tickers

1. Composite Trajectory Verdict

Given CPSS's specialty finance business model reliant on net interest spread from auto receivables funded via securitizations and warehouse lines, the income statement (net interest margin trends) and cash flow statement (operating cash generation relative to purchase volumes) carry the most weight, with the balance sheet indicating funding capacity and leverage.

Composite Trajectory: Mixed

Earnings show revenue growth (+10.4% annually, +7.9% YTD) and recent quarterly net income improvement (+30% in Q2 2026, +24% YTD), but annual net interest margin compressed from 5.4% to 5.2% and quarterly YTD margin slipped to 5.1% from 5.2%. Cash flow from operations strengthened significantly (+23.6% annually, +48% YTD), yet investing outflows grew faster, requiring heavy warehouse financing advances ($354.4M net advances in YTD 2026 vs $16.6M net repayments in YTD 2025). The balance sheet reflects portfolio expansion (managed portfolio +16.1% YTD) but leverage increased (liabilities/equity 12.9x vs 11.5x annually) and unrestricted cash remains minimal ($7.5M), with warehouse availability dropping to $43.4M against $725M capacity.

2. Red Flags

• Net interest margin compression: 5.4% (FY2024) to 5.2% (FY2025) annually; YTD 5.1% vs 5.2% (10-K 2025-12-31, MD&A; 10-Q 2026-06-30, MD&A)
• Unrestricted cash minimal: $6.3M (Dec 2025) and $7.5M (Jun 2026) against $3.9B-$4.4B total assets (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Condensed Balance Sheets)
• Warehouse line utilization near capacity: $679.9M outstanding on $725M capacity (93.8%) with only $20.9M eligible collateral (10-Q 2026-06-30, MD&A Liquidity and Capital Resources; Condensed Balance Sheets)
• Delinquencies plus repossession rising: 13.38% of managed portfolio (Jun 2026) vs 12.16% (Jun 2025) (10-Q 2026-06-30, MD&A Credit Experience)
• Annualized net charge-offs elevated at 7.3% (Q2 2026) (10-Q 2026-06-30, MD&A Credit Experience)
• Sales expense growth outpacing revenue: +45.6% vs +10.6% in Q2 2026; +28.4% vs +7.9% YTD (10-Q 2026-06-30, MD&A and Condensed Statements of Operations)
• Cross-default provisions across securitization and non-securitization debt (10-K 2025-12-31, MD&A Liquidity and Capital Resources)
• Fair value marks positive but declining: $21.0M (FY2024) to $6.5M (FY2025) to $0 in recent quarters (10-K 2025-12-31, Consolidated Statements of Operations; 10-Q 2026-06-30, Condensed Statements of Operations)

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Overall Assessment: Annual revenue grew 10.4% to $434.5M (FY2025 vs FY2024) driven by 15.1% average portfolio growth, but net income was flat at $19.3M vs $19.2M as interest expense rose 21.3% vs 16.1% interest income growth, compressing net interest margin to 5.2% from 5.4%. Quarterly trends show improvement: Q2 2026 net income rose 30% to $6.2M with net interest yield stable at 5.1%, and YTD net income rose 24% to $11.8M though YTD net interest yield dipped to 5.1% from 5.2%. Fair value marks, which boosted revenue in prior periods ($21.0M FY2024, $6.5M FY2025), were $0 in Q1 and Q2 2026. Sales expense surged 45.6% in Q2 and 28.4% YTD on higher contract purchases ($757.7M Q2 vs $433.0M; $1,290.9M YTD vs $884.2M).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Overall Assessment: Operating cash flow grew strongly — $289.0M FY2025 vs $233.8M FY2024 (+23.6%) and $189.9M YTD 2026 vs $128.3M YTD 2025 (+48.0%) — driven by net income and fair value accretion ($139.7M YTD 2026). However, investing cash outflows accelerated sharply to -$697.0M YTD 2026 from -$360.8M YTD 2025 as finance receivable purchases jumped to $1,266.6M from $882.9M. Financing cash flow swung to $515.1M YTD 2026 from $255.3M YTD 2025, primarily from $354.4M net warehouse advances (vs $16.6M net repayments prior year). Free cash flow (operating less investing) remained deeply negative and widened: -$507.1M YTD 2026 vs -$232.5M YTD 2025. Unrestricted cash ended at only $7.5M.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Deteriorating

Overall Assessment: Total assets grew 14.6% YTD to $4,422.2M led by finance receivables at fair value (+15.2% to $4,212.2M). Liabilities grew faster at 15.6% to $4,103.0M, pushing leverage (liabilities/equity) to 12.9x from 11.5x at FY2025. Securitization trust debt rose 4.8% YTD to $3,131.1M while warehouse lines more than doubled to $679.9M from $324.9M, consuming most of the $725M capacity. Residual interest financing increased 18.0% to $168.8M. Shareholders' equity grew only 3.1% to $319.2M, lagging asset growth. Unrestricted cash remained below $10M. The managed portfolio expanded 16.1% YTD to $4,306.7M, but credit metrics softened: delinquencies plus repossession rose to 13.38% from 12.16% a year earlier.

6. Data Gaps

• Quarterly income statements and cash flows for Q3 2025, Q4 2025, and Q1 2025 (only annual FY2024/FY2025 and YTD/Q2/Q1 2026 provided)
• Full 10-Q filings for 2025-09-30 and 2025-06-30 (referenced but truncated in provided documents)
• Explicit Q1 2026 net income figure (derived from YTD less Q2 in 10-Q 2026-06-30)
• Return on equity/assets metrics not disclosed
• Detailed debt maturity schedule beyond contractual obligations table in 10-K (excludes securitization trust debt amortization)
• Breakdown of "Other income" components for FY2025 beyond third-party fees and tax refunds